Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair

William Blair analyst Tim Lugo reiterated an Outperform rating on Collegium Pharmaceutical (NASDAQ: COLL) following Q3 results which showed Xtampza ER sales for the third quarter came in at $11.95 million, well above our expectation of $4.8 million and consensus of $5.3 million. Lugo notes that even if the one-time increase removed, sales would have come in at $7.6 million, still above both our and consensus estimate.

"With a strengthened formulary position at Cigna, Humana, UnitedHealth, and others as well as an improved label and associated marketing plan, we anticipate accelerated sales growth in 2018," Lugo added.

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $10.03 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
• Morgan Stanley Upgrades Sonova Holding AG (SOON:SW) (SONVY) to Equalweight
• UBS Starts Compass Gas e Energia SA (PASS3:BZ) at Buy